¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Human blood coagulation factor VIII"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • factor XI
    Á¦11ÀÎÀÚ
  • factor XII
    Á¦12ÀÎÀÚ
  • factor XIII
    Á¦13ÀÎÀÚ
  • granulocyte colony-stimulating factor
    °ú¸³±¸Áý¶ôÀÚ±ØÀÎÀÚ
  • granulocyte-macrophage colony-stimulating factor
    °ú¸³±¸Å«Æ÷½Ä¼¼Æ÷Áý¶ôÀÚ±ØÀÎÀÚ, °ú¸³±¸´ë½Ä±¸Áý¶ôÀÚ±ØÀÎÀÚ
  • growth factor
    ¼ºÀåÀÎÀÚ
  • hyperglycemic-glycogenolytic factor
    °íÇ÷´ç±Û¸®ÄÚ°ÕºÐÇØÀÎÀÚ
  • hematopoietic growth factor
    Ç÷¾×Çü¼º¼ºÀåÀÎÀÚ, Á¶Ç÷¼ºÀåÀÎÀÚ
  • histamine sensitizing factor
    È÷½ºÅ¸¹Î¹Î°¨ÀÎÀÚ
  • host integration factor
    ¼÷ÁÖÅëÇÕÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • initiation factor
    ½ÃÀÛÀÎÀÚ
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • ketogenic factor
    ÄÉÅæ»ý¼ºÀÎÀÚ
  • labile factor
    1. ºÒ¾ÈÁ¤ÀÎÀÚ 2. ºÒ¾ÈÁ¤¿ä¼Ò
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • blood gas solubility coefficient
    Ç÷¾×°¡½º¿ëÇØ°è¼ö
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çü±º
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • blood oxygenation level dependant contrast
    Ç÷Áß»ê¼ÒÄ¡ÀÇÁ¸´ëÁ¶µµ
  • blood pool scan
    Ç÷¾×¿õµ¢À̽ºÄµ, Ç÷¾×Àú·ù½ºÄµ
  • blood pressure crisis
    Ç÷¾ÐÀ§±â
  • blood pressure cuff
    Ç÷¾ÐÃøÁ¤¶ì
  • blood pressure fluctuation
    Ç÷¾Ðº¯µ¿, Ç÷¾Ð±âº¹
  • blood pressure manometer
    Ç÷¾Ð°è
  • blood stained sputum
    Ç÷¾×Âø»ö°¡·¡
  • blood sugar test
    Ç÷´ç°Ë»ç
  • blood tinged sputum
    Ç÷¾×ÈçÀû°¡·¡
  • blood transfusion reaction
    ¼öÇ÷¹ÝÀÀ
  • blood urea nitrogen
    Ç÷¾×¿ä¼ÒÁú¼Ò
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ.
  • plasma factor
    Ç÷ÀåÀÎÀÚ(úìíìì×í­), ÇöóÁÀÎÀÚ(¡­ì×í­)
  • plasma thromboplastic factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • plasma thromboplastin factor
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾ÀÎÀÚ.
  • platelet activating factor
    Ç÷¼ÒÆÇ Ȱ¼º ÀÎÀÚ
  • platelet factor 4
    Ç÷¼ÒÆÇÀÎÀÚ(úìá³÷ùì×í­) 4
  • platelet factor 4=PF4
    Ç÷¼ÒÆÇÀÎÀÚ 4
  • platelet factor III
    Ç÷¼ÒÆÇÁ¦»ïÀÎÀÚ.
  • platelet-activating factor (PAF)
    Ç÷¼ÒÆÇ Ȱ¼ºÈ­ÀÎÀÚ
  • platelet-activating factor (paf)
    Ç÷¼ÒÆÇȰ¼ºÈ­ÀÎÀÚ(úìá³÷ùüÀàõûùì×í­)
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡ Áõ½ÄÀÎÀÚ
  • platelet-derived growth factor(PDGF)
    Ç÷¼ÒÆÇ À¯·¡ ¼ºÀå ÀÎÀÚ
  • platelet-derived growth factor(pdgf)
    ÆÇ-À¯µµ¼ºÀåÀÎÀÚ(úìá³÷ù-ë¯Óôà÷íþì×í­)
  • power factor
    Ãâ·Â·ü(õóæ³ëÒ), ¿ª·ü(æ³ëÒ).
  • predisposing factor
    ¼ÒÀμº ¿äÀÎ, ¼±Çà¿äÀÎ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
  • dose-reduction factor
    ¼±·®°¨¼Ò°è¼ö
  • drug resistance factor
    ¾àÁ¦³»¼ºÀÎÀÚ
  • drug resistance transfer factor
    ¾àÁ¦³»¼ºÀü´ÞÀÎÀÚ
  • duplicate factor
    Áߺ¹ÀÎÀÚ.
  • early pregnancy factor(EPF)
    ÃʱâÀÓ½ÅÀÎÀÚ
  • edaphic factor
    ÅäÁöÀÎÀÚ(ÊÙËöËö).
  • elongation factor
    ¿¬ÀåÀÎÀÚ(¡­ì×í­).
  • elongation factor
    ½ÅÀåÀÎÀÚ
  • enabling factor
    ÀÇ·áÀÌ¿ë °¡´É¿äÀÎ.
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ
  • encephalitogenic factor
    ³ú¿°À¯¹ßÀÎÀÚ.
  • endothelial cell growth factor
    ³»ÇǼ¼Æ÷ Áõ½ÄÀÎÀÚ
  • endothelium-derived contracting factor (EDCF)
    ³»ÇǼ¼Æ÷¼º¼öÃàÀÎÀÚ(Ò®ù«á¬øààõâ¥õêì×í­)
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ.
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷¼º ÀÌ¿ÏÀÎÀÚ(¡­ì¬èÐì×í­).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
HRV heart rate variability; human reovirus; human rotavirus
HSP Health Systems Plan; heat shock protein; hemostatic screening profile; Henoch-Schonlein purpura; her...
HTL hamster tumor line; hearing threshold level; high-L-leucine transport; histotechnologist; human T-ce...
HTLV human T-cell leukemia/lymphoma virus; human T-lymphotropic virus
HTS head traumatic syndrome; HeLa tumor suppression; human thyroid-stimulating hormone, human thyroid st...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 16
HB-EGF Heparin binding epidermal growth factor-like growth factor
HB-EGF Heparin-binding epidermal growth factor (EGF)-like growth factor
HGF Hepatocyte Growth Factor-Scatter Factor
HGF-SF Hepatocyte Growth Factor-Scatter Factor
SF/HGF Scatter factor/hepatocyte growth factor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • emotional factor
    Á¤¼­ ¿äÀÎ
  • enabling factor
    ÀÇ·á ÀÌ¿ë °¡´É ¿äÀÎ
  • endogenous factor
    ³»Àμº ¿ä¼Ò
  • endothelium-derived relaxing factor
    ³»ÇÇ ¼¼Æ÷¼º ÀÌ¿Ï ÀÎÀÚ
  • endurance factor
    Áö¼Ó ÀÎÀÚ
  • environmental chemotactic factor
    ȯ°æ¼º È­ÇÐ ÁÖ¼º ÀÎÀÚ
  • eosinophil chemotactic factor
    È£»ê±¸ È­ÇÐ ÁÖ¼º ÀÎÀÚ
  • excess factor
    °úÀ× ÀÎÀÚ
  • F factor
    ¿¡ÇÁ ÀÎÀÚ
    ´ëÀå±Õ¿¡¼­ ¿õ¼ºÀ» ºÎ¿©ÇÏ´Â ÀÛ¿ëÀ» °¡Áø ¿¡ÇǼؼº ÀÎÀÚ. ÀÌ ÀÎÀÚ°¡ ÀÖ´Â ¼¼±ÕÀ» F¶ó ÇÏ¸ç ¿õ¼ºÀ» ³ªÅ¸³»°í, À̰ÍÀÌ ¾ø´Â °ÍÀ» F¶ó°í ÇÏ¿© ÀÚ¼ºÀ» ³ªÅ¸³½´Ù. µÎ ¼¼Æ÷¸¦ È¥ÇÕ ¹è¾çÇϸé Á¢ÇÕÀÌ ÀϾ F ¼¼Æ÷ÀÇ F ÀÎÀÚ´Â F ¼¼Æ÷·Î µé¾î°¡ ÀÚ¼ºÀ» ¿õ¼ºÀ¸·Î ¹Ù²Û´Ù. F ÀÎÀÚ¿¡ ¼¼±Õ ¿°»öüÀÇ ÀϺκÐÀÌ ºÎÂøµÇ¾î ÀÖ´Â »óŸ¦ F'¶ó Çϰí, F ÀÎÀÚ°¡ ¼¼±Õ ¿°»öü ¼ÓÀ¸·Î µé¾î°£ »óÅÂÀÇ °ÍÀ» Hfr
  • factor
    ÀÎÀÚ
    °á°ú »êÃâ¿¡ ÇÊ¿äÇÑ ÀÛ¿ëÀ̳ª ¹°Áú. ¿¹ÄÁ´ë ÀÀ°í ÀÎÀÚ. º¸Åë ÀÛ¿ë ±âÀüÀ̳ª È­ÇÐÀû ¼ºÁúÀÌ ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀº ¹°ÁúÀ» °¡¸£Å°´Âµ¥ ¾²ÀÌ´Â ¿ë¾î·Î ³»ºÐºñ ¿µ¿ª¿¡¼­´Â ±× ÀÎÀÚÀÇ È­ÇÐÀû ¼ºÁúÀÌ ±Ô¸íµÈ ÈÄ¿¡´Â 'È£¸£¸ó'À̶ó°í °³ÄªÇÑ´Ù.
  • factor deficiency
    ÀÎÀÚ °áÇÌ, Á¦ÀÎÀÚ °áÇÌÁõ
  • factor IX deficiency
    Á¦ 9ÀÎÀÚ °áÇÌÁõ, Á¦9ÀÎÀÚ °áÇÌ
  • factor macrophage migration inhibition
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ
  • factor VII deficiency
    Á¦ 7ÀÎÀÚ °áÇÌÁõ
  • factor XI deficiency
    Á¦11ÀÎÀÚ °áÇÌ
    ÀÌ ÀÎÀÚ°¡ ºÎÁ·µÇ¸é Ç÷¿ìº´ C³ª Rosenthal ÁõÈıºÀ¸·Î ºÒ¸®´Â Àü½Å¼º Ç÷¾× ÀÀ°í Àå¾Ö¸¦ ÀÏÀ¸Å°´Âµ¥ °íÀüÀû Ç÷¿ìº´°ú À¯»çÇÏ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 16
blood plastid Any basic, morphologic unit in the biologic composition of blood, e.g., an erythrocyte.
(05 Mar 2000)
blood platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.
(12 Dec 1998)
blood poisoning See: septicaemia, pyaemia.
(05 Mar 2000)
blood pool imaging Nuclear medicine study using a radionuclide that is confined to the vascular compartment.
(05 Mar 2000)
blood porphyrin level A test which is used to measure red blood cell porphyrin levels. Porphyrins are pigments found in both animal and plant life.
This test is useful in evaluating any number of porphyrin disorders (involving the various porphyrins) of red blood cells.
Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia.
Increased protoporphyrins may be seen in infection, thalassaemia, sideroblastic anaemia, iron deficient anaemia, increased erythropoiesis and lead poisoning. Increased uroporphyrins may indicate congenital erythropoietic porphyria or erythropoietic protoporphyria.
(27 Sep 1997)
blood pressure <cardiology, physiology> The force that the circulating blood exerts on the walls of the arteries.
This measurement is divided into systolic (pressure during contraction of the heart) and diastolic (pressure during relaxation phase).
Blood pressure varies with age and sex of the individual. A rough rule of thumb for normal systolic pressure is 100 + Age of individual. In children 2 x (age) + 80 = systolic BP The diastolic pressure should be roughly 2/3 the systolic pressure.
(27 Sep 1997)
blood pressure determination Techniques for measuring blood pressure.
(12 Dec 1998)
blood pressure, high High blood pressure (hypertension) is a repeatedly elevated blood pressure exceeding 140 over 90 mmHg. High blood pressure is also called the silent killer. Chronically high blood pressure can cause blood vessel changes in the back of the eye (retina), thickening of the heart muscle, kidney failure, and brain damage. No specific cause for high blood pressure is found in 95% of patients. High blood pressure is treated with salt restriction, regular aerobic exercise, and medications.
(12 Dec 1998)
blood pressure monitoring, ambulatory Method in which prolonged blood pressure readings are made while the patient undergoes normal daily activities. It allows quantitative analysis of the high blood pressure load over time, can help distinguish between types of hypertension, and can assess the effectiveness of antihypertensive therapy.
(12 Dec 1998)
blood pressure monitors Devices for continuously measuring and displaying the arterial blood pressure.
(12 Dec 1998)
blood products Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered.
(14 Nov 1997)
blood protein electrophoresis Electrophoresis applied to blood proteins.
(12 Dec 1998)
blood proteins The hundreds of different proteins present in blood plasma, including carrier proteins (such as serum albumin, transferrin, and haptoglobins), fibrinogen and other blood coagulation factors, complement components, immunoglobulins, enzyme inhibitors, precursors of substances such as the angiotensins and bradykinin, and many other types of proteins.
(12 Dec 1998)
blood puzzles Foreign bodies or deformed blood cells that may be misinterpreted as infectious agents (e.g., bacteria, fungi) in stained films as a result of similarities in morphology and staining properties.
(05 Mar 2000)
blood relationship A relationship that share a common bloodline, descent from a common ancestor.
(27 Sep 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 16
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 16
ÅëÇÕ°Ë»ö ¿Ï·á